MDx/CDx Focus: 23andMe Still Working with FDA; Aetna Lists Medically Necessary, Investigational Dx | GenomeWeb

While Working with FDA, 23andMe Offers Customers No Timeline for Reporting Health-related Results

Consumer-focused genetic testing firm 23andMe is working with the US Food and Drug Administration to meet regulatory requirements so that it can return certain health-related reports to its customers. However, in a recent update to customers, the company was unable to provide a timeline for when this might occur.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

BGI CEO Ye Yin says that mapping variation within the human genome will bring a "big data revolution" to healthcare, Wired UK writes.

All the images that investigators produce through their research present a challenge to share, Nature News reports.

The House of Representatives science committee has approved a measure that includes new rules for large National Science Foundation projects, ScienceInsider reports.

In PLOS this week: founder mutation linked to some leukoencephalopathy cases, transcript and protein profiles of the kissing bug, and more.